The research ... recommended Mounjaro – also known as tirzepatide and made by Eli Lilly – for people with a body mass index (BMI) of more than 35 and at least one weight-related illness.
Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of ...
Tirzepatide does not yield a significant increase in pancreatitis risk despite elevating pancreatic enzyme levels, according to study findings published in Obesity Science and Practice. Tirzepatide, a ...
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Female volunteers age 13-70 who have anorexia nervosa and recently lost weight are needed for research participation at the JHU East ... email [email protected] with the subject line "Gut Peptide Study." ...
Peptide synthesis plays a pivotal role in drug development, diagnostics, and therapeutic applications. The market’s expansion is fueled by increased research into peptide-based therapeutics, ...
The approved dose of Niktimvo for adults and pediatric patients weighing at least 40 kg is 0.3 mg/kg, up to a maximum dose of 35 mg, as an intravenous infusion over 30 minutes every two weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback